16 results about "Diclofenac Sodium" patented technology

The invention discloses application of a small molecule compound in targeting TOPBP1 protein, and belongs to the technical field of biological medicine. The application verifies that various small molecular compounds, namely diclofenac sodium, zaltoprofen, quinine and adamantine acetic acid, can be combined with the BRCT 7-8 structural domain of the TOPBP1, so as to target the TOPBP1 protein, and the dissociation equilibrium constant of the combination is between 100 and 250 mu M. And through AI model prediction, X-ray crystallography technology and the like, the combined action mechanism is disclosed. The application proves that diclofenac sodium, zaltoprofen, quinine and adamantane acetic acid as a class of small molecular compounds have the potential of serving as candidate molecules of antitumor drugs.

The invention belongs to the technical field of fine chemical engineering, and particularly relates to a device for fully continuously synthesizing diclofenac sodium. A multi-step continuous reaction system is adopted, and continuous production of diclofenac sodium is achieved through a feeding pump, a mixer, a micro-channel reactor, a rotary dynamic reactor, a buffer tank, a back pressure valve, a continuous kettle type reactor and a continuous crystallizer which are sequentially connected. The device can ensure the consistency and stability of product quality, and is high in integration degree, small in occupied area for production and high in unit productivity. Meanwhile, the yield can be adjusted according to requirements, the amplification effect existing in a traditional kettle type process is avoided, and the reagent dosage and three-waste emission can be reduced. Compared with the prior art, the method has the advantages that the quality stability is obviously improved, and the production cost is also reduced.

Disclosed is a method for relieving cancer pain in a patient. The method comprises administering a patch to a patient in need thereof, wherein the patch comprises a backing layer and an adhesive layer laminated on the backing layer, the adhesive layer comprises an adhesive base and 150 mg to 225 mg of diclofenac sodium, and wherein the patch is applied once a day.

The present invention discloses the preparation and therapeutic properties of a gel consisting of the active ingredients diclofenac sodium and lysine clonixinate, which are combined for the first time for the topical treatment of pain in musculoskeletal inflammatory processes.

The utility model discloses a kind of sampling devices for diclofenac sodium sustained-release suppository detection, including sampling cylinder, the bottom of the sampling cylinder is communicated with sampling needle, the inside of the sampling cylinder is slidably connected with piston, the top of the piston is fixedly installed with pull rod, the top of the pull rod is fixedly installed with handle, the utility model is rotated by rotating sleeve, so that two traction plates move to two sides respectively, square bar and clamping plate are moved by traction plate movement, after clamping plate moves and no longer contacts sampling cylinder, support plate can be slid on the surface of sampling cylinder, after sliding to appropriate position, by rotating rotating sleeve, so that abutment rod no longer contacts traction plate, clamping plate can be reset and clamp the surface of sampling cylinder at this time, sampling needle at the bottom of sampling cylinder is inserted into suppository bottle after this, the effect of sampling at the same depth can be achieved, and the height of sampling needle extending into bottle can be adjusted simultaneously.

To provide a topical pharmaceutical composition containing indomethacin, diclofenac sodium, felbinac, salicylic acids, or heparins, wherein irritation to the application site is reduced. [Solution] A topical pharmaceutical composition that contains component (A) and component (B) below, wherein component (A) is one or more selected from the group consisting of components (A-1) to (A-5) below, and which reduces irritation to the application site. Ingredient (A-1): Indomethacin Ingredient (A-2): Diclofenac sodium Ingredient (A-3): Felbinac Ingredients (A-4): Salicylic acids Ingredient (A-5): Heparinoid Ingredient (B): One or more selected from the group consisting of loxoprofen, its salts, and their hydrates.

The utility model discloses a kind of rapid cooling support for diclofenac sodium sustained-release suppository, including base, the base top surface is equipped with multiple top rods, multiple connecting rods are installed on the outer side of the top rod, the connecting rod one end is equipped with narrow part, the narrow part upper end is equipped with guide part, the both sides of the base are equipped with through slot, the through slot inboard is slidably installed with through plate, the through plate one end is equipped with support rod, the support rod one end is fixedly installed with the stop lever that is contacted with the top of mould. The utility model is limited to suppository mould different position by top rod, stop lever and multiple narrow parts together, and support smaller to mould blocking, when mould passes through forced air cooling tunnel rapid cooling, it can help to improve mould cooling efficiency, prevent suppository mould surface to form heat dissipation dead angle.

The invention discloses a clofenyellow tablet and a coating process thereof, and belongs to the technical field of production of the clofenyellow tablet. The preparation method comprises the following steps: sieving dihydroxyaluminium aminoacetate to obtain dihydroxyaluminium aminoacetate superfine powder, adding a cosolvent, a solubilizer and purified water, uniformly mixing to form dihydroxyaluminium aminoacetate compound mixed liquor, uniformly mixing the dihydroxyaluminium aminoacetate compound mixed liquor, a thickening agent, a filling agent and purified water to obtain coating liquid, and finally spraying the coating liquid on a lofenac-huangsensitive tablet, thereby obtaining the lofenac-huangsensitive tablet. And drying to obtain the lofenac yellow tablet. According to the invention, a film coating in a conventional process is replaced by a medicine (dihydroxyaluminum glycinate) coating, so that the moisture-proof, oxygen-isolating, wear-resistant and shading functions of the lofenac sodium tablet are enhanced, and the content of impurities B and C in diclofenac sodium is effectively reduced. Experiments show that the medicine irritation can be effectively reduced, adverse reactions such as vomiting and diarrhea can be reduced, gastrointestinal peristalsis can be better increased, the gastrointestinal motility function can be promoted, the safety of the medicine is greatly improved, and the medicine has a wide application scene.

The present inventors primarily aimed to provide an ointment containing diclofenac sodium in which the formation of diclofenac analogs is suppressed. [Solution] The above problem can be solved by an ointment containing diclofenac sodium and oleic acid, wherein the oleic acid content is below a predetermined concentration.

1. The name of the design product: packaging box (dichloris sodium sustained-release tablets). 2. The use of the design product: for product outer packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

A composition for treatment of pain and inflammation in humans includes 4.0-10.0% Diclofenac Sodium by weight, 2.0-6.0% Gabapentin by weight, 1.0-2.0% Baclofen by weight, and 2.0-5.0% Cyclobenzaprine by weight. Other compositions are also disclosed.

This invention provides a probiotic composition for the prevention and / or treatment of vaginal infections and related diseases, and its use therein. The probiotic composition comprises *Lactobacillus curvatureii*, *Lactobacillus jenny*, *Lactobacillus gasseri*, *Lactobacillus plantarum*, and *Lactobacillus fermentum*. Experiments have demonstrated that the probiotic composition of this invention achieves better efficacy in treating vaginal infections, especially VVC, compared to single-strain probiotics and positive control drugs such as metronidazole suppositories and diclofenac sodium.

The invention relates to a pain-relieving nano pasting film with a multi-layer composite structure and a preparation process of the pain-relieving nano pasting film, and belongs to the technical field of pasting film preparation. The genipin, the gelatin and the glutamine transaminase are added in the preparation process, so that the state that the collagen is dissolved when encountering water is changed, and the film achieves a slow-release effect; in addition, non-steroidal anti-inflammatory drugs such as diclofenac sodium or ibuprofen arginine are added, and the analgesic effect of the finished product is increased through synergism of the analgesic effect, the antipyretic effect and the effect of inhibiting synthesis of prostaglandin at the inflammation part. The pain-relieving nano pasting film prepared by the invention is a multi-dimensional three-dimensional film woven by multiple processes, the first layer of film is film cloth formed by modifying collagen through system active components and then spinning, and the pain-relieving nano pasting film not only can quickly transdermally relieve pain, but also can continuously release medicines; the second layer of film is an imitated human body sebum film and can effectively lock medicinal components; the pain-relieving nano pasting film prepared by the preparation process is light, thin and comfortable, is fit and free of burden in use, and does not irritate skin.

The invention discloses a diclofenac sodium injection and a preparation method thereof.According to the diclofenac sodium injection, polyoxyethylated castor oil and vitamin E TPGS serve as main solubilizers, the solubility of diclofenac sodium is improved synergistically, meanwhile, local irritation of the injection is reduced, the injection can tolerate terminal sterilization at the temperature of 121 DEG C, and the injection is safe and reliable. After sterilization, the product is still clear and transparent, and the content and related substances change little; according to the injection, the types and the dosage of auxiliary materials are small, the potential safety risk is reduced, and the quality requirement of the injection is met.

The invention discloses a medicine for treating coronary heart disease and myocardial infarction and a taking method thereof. The medicine comprises the following components in specific parts by weight: Yunnan Baiyao semen saussureae, Liushen pills, sinew-strengthening tablets, vitamin B1 and diclofenac sodium enteric-coated tablets. The medicine is orally taken three times a day, one treatment course comprises seven days, and one treatment course every year. According to the principle, all the components have a synergistic effect in the aspects of relieving spasm, eliminating thrombus, dredging collaterals, relieving pain, promoting energy metabolism, relieving inflammation and edema and the like. The medicine has the advantages that the treatment effect is remarkable, myocardial blood supply can be improved, peduncle formation is avoided, relapse is prevented and sequelae are improved when patients with embolism take the medicine; the medicine is convenient to take, and the medicine taking frequency and period are greatly reduced; the safety is high and the side effect is small. Clinical studies show that in a grouped experiment of 200 patients, compared with a control group, the experimental group has significant difference (Plt, Plt) in the aspects of symptoms, electrocardiogram, myocardial zymogram, recurrence rate, sequelae improvement and the like; 0.05), and the traditional Chinese medicine composition has great clinical popularization value.

A tablet press tablet discharging device and a preparation process for diclofenac sodium enteric-coated tablets. The tablet press tablet discharging device comprises a tablet discharge chute (1) having a feed inlet and a discharge outlet (19), the chute bottom inclining downward along a discharge direction; at least three elastic plates (32) each capable of rotating between a first position and a second position are pivotally connected to the tablet discharge chute (1); the elastic plates (32) are arranged in a staggered manner and divide the tablet discharge chute (1) into a primary separation chamber (1a) and at least two secondary separation chambers (1b, 1c) along the discharge direction, the primary separation chamber (1a) and the secondary separation chambers (1b, 1c) being each provided with a set of sieve holes (13) at the chute bottom, the diameter of the sieve holes (13) being less than that of tablets, and each elastic plate (32) being arranged on the side of a set of sieve holes (13) closer to the discharge outlet (19); dust collection mechanisms (4) correspond to the sieve holes (13) and each comprise a powder collection box (42) and a dust collector (44), the powder collection boxes (42) being arranged below the sieve holes (13), and the dust collectors (44) being communicated with the powder collection boxes (42) by means of pipes; when each elastic plate (32) is at the first position, the tablets are blocked by the elastic plate (32); and when each elastic plate (32) is at the second position, the tablets are released and slide towards the discharge outlet. The tablet discharging device can promptly and effectively remove drug powders, thus ensuring a highly uniform coating effect for tablets.